Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: A randomized, placebo-controlled crossover trial

Journal of Infectious Diseases

Volumn 210, Issue 5, 2014, Pages 708-712

  Yi, Tae Joon ^a,b   Shannon, Brett ^a,b   Chieza, Lisungu ^c   Su, Desheng ^b   Saunders, Megan ^c   Tharao, Wangari ^c   Huibner, Sanja ^a,b   Remis, Robert ^b   Raboud, Janet ^b   Kaul, Rupert ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Dalla Lana School of Public Health University of Toronto ^*  (Canada)

Author keywords

Acyclovir; Cervix; Co infections; Female genital tract; HIV; HSV 2; Mucosal immunology; STI; Susceptibility; Valacyclovir

Indexed keywords

CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; VALACICLOVIR;

ADULT; AGED; ARTICLE; CANADA; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TREATMENT DURATION; UTERINE ENDOCERVIX; WOMEN'S HEALTH;

ACYCLOVIR; CERVIX; CO-INFECTIONS; FEMALE GENITAL TRACT; HIV; HSV-2; MUCOSAL IMMUNOLOGY; STI; SUSCEPTIBILITY; VALACYCLOVIR;

ACYCLOVIR; ADULT; AGED; ANTIVIRAL AGENTS; CANADA; CD4-POSITIVE T-LYMPHOCYTES; CERVIX UTERI; CROSS-OVER STUDIES; CYTOKINES; DENDRITIC CELLS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; VALINE; YOUNG ADULT;

EID: 84901267036     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu163     Document Type: Article

References (15)

1. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
2. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptorpositive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-92.
3. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-23.
4. Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589-98.
5. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-71.
6. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-19.
7. Remis RS, Liu J, Loutfy M, et al. The epidemiology of sexually transmitted co-infections in HIV-positive and HIV-negative African-Caribbean women in Toronto. BMC Infect Dis 2013; 13:550.
8. Kessler HH, Muhlbauer G, Rinner B, et al. Detection of herpes simplex virus DNA by real-time PCR. J Clin Microbiol 2000; 38:2638-42.
9. McKinnon LR, Nyanga B, Chege D, et al. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol 2011; 187:6032-42.
10. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 2009; 106:20877-82.
11. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003; 300:1295-7.
12. Fichorova RM, Morrison C, Doncel G, et al. Association between STI/ RTI infections, altered cervical innate immunity and HIV-1 seroconversion among hormonal contraceptive users [abstract WEAC201]. In: International AIDS Conference, Washington, DC, 2003.
13. Shannon B, Yi TJ, Thomas-Pavanel J, et al. Impact of asymptomatic herpes simplex virus type 2 infection on mucosal homing and immune cell subsets in the blood and female genital tract. J Immunol 2014 (In Press).
14. Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 2012; 379:641-7.
15. MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother 2004; 53:899-901.